Larson Financial Group’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
BBA
Larson Financial Group's NRIX Position: Q3 2026 in Review
Larson Financial Group increased its Nurix Therapeutics (NRIX) stake by 3.9% in Q3 2026, buying an estimated $424 and bringing the position to 458 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2465.
Larson Financial Group first reported a position in NRIX in Q3 2024 and has held it in 6 quarters since. The position peaked at $29.2K in Q4 2025. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- Larson Financial Group held 458 shares of Nurix Therapeutics worth $10.9K as of Q3 2026.
- Larson Financial Group bought 17 Nurix Therapeutics shares in Q3 2026, an estimated $424.
- Nurix Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #2465 holding.
- Larson Financial Group first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 6 quarters since.
- Larson Financial Group's Nurix Therapeutics position peaked at $29.2K in Q4 2025.
- 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.